首页> 美国卫生研究院文献>Psychiatry Investigation >Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
【2h】

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

机译:绝经前激素受体阳性乳腺癌中他莫昔芬和戈塞瑞林与单独他莫昔芬之间的恐惧症和促卵泡激素水平:一项为期12个月的前瞻性随机研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveTamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH levels who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) analogue, with tamoxifen.
机译:目的他莫昔芬是一种雌激素受体拮抗剂,用于预防乳腺癌的复发,它可能激起抑郁和焦虑,并增加患者的促卵泡激素(FSH)。我们比较了单独接受常规他莫昔芬和联合治疗戈瑟瑞林(一种促性腺激素释放激素(GnRH)类似物)与他莫昔芬的焦虑和抑郁症状以及FSH水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号